Joslin Clinic Recommendation on Avandia
Monday, September 27, 2010
The following is a recommendation from the Joslin Clinic on the recent decision by the Federal Food and Drug Administration regarding Avandia.
The Food and Drug Administration has placed further restrictions on the use of Avandia (Rosiglitazone) or any medication that contains Avandia (Avandamet or Avandaryl) because of concern that use of this drug may increase risk for heart attacks (myocardial infarction). The restriction means that the drug may be prescribed for new type 2 patients only if they are not able to control their diabetes with any other medications including Actos (pioglitazone). However, current users of Avandia will be allowed to continue to use the medication if they are benefiting from the drug and if they choose to do so.
If you are currently taking Avandia or any combination of medications that include Avandia and have any concerns about continuing this medication, please contact your physician to discuss this. Please do not stop taking this medication unless you have discussed this with your physician, as cessation of this drug may lead to a deterioration in your glucose control.
Clinic News & Notes
Page last updated: October 17, 2018